Summary
Edwards Lifesciences Corporation (EW) reported strong financial performance for the quarter and six months ending June 30, 2014. Net sales increased by 11.2% and 8.2% respectively, driven primarily by growth in Transcatheter Heart Valves, particularly in Europe with the launch of the Edwards SAPIEN 3 valve. A significant event was the settlement of patent litigation with Medtronic, Inc., which resulted in a one-time upfront payment of $750.0 million to Edwards Lifesciences, substantially boosting net income for the period. Despite this one-time gain, the company's core operations demonstrated healthy sales expansion across its key product segments: Transcatheter Heart Valves, Surgical Heart Valve Therapy, and Critical Care.
Financial Highlights
46 data pointsBeta
Financial Statements
Beta
| Revenue | $575.10M |
| Cost of Revenue | $151.20M |
| Gross Profit | $423.90M |
| R&D Expenses | $89.10M |
| SG&A Expenses | $215.50M |
| Net Income | $547.00M |
| EPS (Basic) | $0.86 |
| EPS (Diluted) | $0.85 |
| Shares Outstanding (Basic) | 633.60M |
| Shares Outstanding (Diluted) | 644.40M |
Key Highlights
- 1Total net sales increased by 11.2% to $575.1 million for the three months ended June 30, 2014, and by 8.2% to $1,097.5 million for the six months ended June 30, 2014.
- 2Transcatheter Heart Valves sales showed robust growth of 20.6% and 16.2% for the three and six months, respectively, fueled by the SAPIEN 3 launch in Europe and SAPIEN XT launch in Japan.
- 3A significant one-time litigation settlement with Medtronic, Inc. resulted in an upfront payment of $750.0 million, substantially increasing net income to $547.0 million for the quarter and $607.3 million for the six months.
- 4Gross profit margin decreased slightly to 73.7% for the quarter and 72.9% for the six months, attributed to foreign currency impacts and a sales reserve for transcatheter heart valve product returns related to new product introductions.
- 5Selling, General, and Administrative (SG&A) expenses increased, primarily due to higher sales and marketing expenses to support the Transcatheter Heart Valve program and a larger incentive compensation accrual.
- 6Research and Development expenses remained robust, representing 15.5% and 15.9% of net sales for the respective periods, indicating continued investment in innovation.
- 7The company announced a new Five-Year Credit Agreement providing up to $750.0 million in borrowings, replacing the previous facility, and continued its share repurchase program.